Proposed Combination Products Rule Underestimates the Cost to Industry

International Medical Device Regulatory Monitor
The U.S. Food and Drug Administration’s (FDA) proposed rule on good manufacturing practices (GMPs) for combination products grossly underestimates the burden of applying certain cGMP requirements to device-drug combinations, a device company says.

To View This Article:


Buy This Article Now

Add this article to your cart for $20.00